SCHEMBL26693529

SCHEMBL26693529

Cc1oc2ccc(OCc3ccccc3)cc2c1Br

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 2/20 0.65
SENP8 Q96LD8 2/20 0.65
SENP7 Q9BQF6 2/20 0.65
SENP6 Q9GZR1 2/20 0.65
L3MBTL1 Q9Y468 2/20 0.62
PKM P14618 1/20 0.62
SLC26A4 O43511 5/20 0.59
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
BLM P54132 1/20 0.59
ATM Q13315 1/20 0.59
MAOB P27338 4/20 0.53
ACHE P22303 1/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.53
MAOA P21397 3/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
ALOX5 P09917 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26693543 0.81 CASP3 (0.66) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL6976339 0.81 CASP3 (0.62) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL24470655 0.80 CASP3 (0.84) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL29713158 0.80 CASP3 (0.84) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL5746156 0.79 CASP3 (0.63) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL26693545 0.79 CASP3 (0.63) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL4124805 0.79 CASP3 (1.00) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL24470563 0.79 CASP3 (0.77) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL24470537 0.78 CASP3 (0.80) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL24470816 0.78 CASP3 (0.80) CASP3SENP8SENP7SENP6L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346583-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US disclosed
EP-4532012-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
WO-2023227696-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023227696-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346583-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 CASP3 572/4885SENP8 2867/4885SENP7 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.